Primatene Mist To Be Unavailable After 2010 – Proposed Rule
This article was originally published in The Tan Sheet
Executive Summary
Wyeth will allow its epinephrine-containing Primatene Mist metered-dose inhaler to be phased out of the market after 2010, rather than reformulating to comply with an FDA proposed rule published in the Sept. 20 Federal Register
You may also be interested in...
Armstrong Says FDA "Assured" OTC Access Of Reformulated Primatene Mist
Armstrong Pharmaceuticals says FDA "assured" the firm that it can sell a proposed reformulated epinephrine inhaler OTC, if approved, despite opponents who say asthma relief is an inappropriate self-medication indication
Armstrong Says FDA "Assured" OTC Access Of Reformulated Primatene Mist
Armstrong Pharmaceuticals says FDA "assured" the firm that it can sell a proposed reformulated epinephrine inhaler OTC, if approved, despite opponents who say asthma relief is an inappropriate self-medication indication
Armstrong Says FDA "Assured" OTC Access Of Reformulated Primatene Mist
Armstrong Pharmaceuticals says FDA "assured" the firm that it can sell a proposed reformulated epinephrine inhaler OTC, if approved, despite opponents who say asthma relief is an inappropriate self-medication indication